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Abstract 
 
Background: Animal models of drug abuse treat nicotine as the primary reinforcing 
agent that promotes tobacco addiction. However, rodents demonstrate poor self-administration 
of nicotine despite evidence of tobacco's high abuse potential in humans. This discrepancy has 
been attributed to other constituents of tobacco smoke that facilitate the development of 
nicotine dependence. 
Objectives: This study aimed to determine whether rats would self-administer 
intravenous an aqueous tobacco smoke extract (TPM) to find evidence if it was more 
reinforcing than nicotine alone. The study also evaluated the role of tobacco smoke 
constituent’s harman and norharman in any differences observed.  
Methods: Firstly, male Sprague-Dawley rats (n=29) were assigned to treatment groups: 
nicotine (30.0μg/kg/infusion), TPM (containing 30.0μg/kg/infusion nicotine) or saline vehicle. 
Ability for each treatment to support intravenous self-administration was assessed using 
spontaneous acquisition of responding on gradually increasing fixed ratio schedules (FR1, 
FR2, FR5). Subsequent progressive ratio (PR) testing was employed to determine reinforcing 
efficacy of each treatment. Then a second group of rats (N = 56) were assigned to treatment 
groups: nicotine alone (30.0 or 75.0μg/kg/infusion) or nicotine combined with norharman (0, 
0.4, 2.5 or 6.25μg/kg/infusion) and harman (0.0, 1.6 or 10.0μg/kg, IP), and tested using a 
similar protocol. 
Results: Animals readily acquired self-administration responding for TPM and produced 
higher PR breakpoints (BP) than rats treated with nicotine alone or vehicle. Rats trained to 
respond for a larger dose of nicotine demonstrated significantly greater response rates than 
those receiving the lower dose of nicotine. Finally, the addition of harman and norharman to 
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nicotine significantly reduced BP at the lower unit dose of nicotine tested. 
Conclusions: These findings support the hypothesis that TPM is more reinforcing than 
nicotine alone. However, the increased reinforcing efficacy of TPM cannot be attributed to the 
actions of harman and norharman. The potential role of serotonin inhibition in tobacco reward 
processes is discussed. 
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Introduction 
 
Tobacco addiction is considered the prototypical substance abuse condition (US DHHS, 
1988) with roughly one quarter of the world’s adult population currently addicted to tobacco 
products (WHO, 2008). For western populations the prevalence of tobacco dependence far 
outstrips that of other substance disorders as defined by DSM criteria (Anthony et al., 1994; 
Kandel et al., 1997). In New Zealand alone approximately 20% of the population self-report 
regular use of tobacco products, with a higher rate of use amongst youth populations (WHO, 
2009). Up to 75% of cigarette smokers express a desire to discontinue use, but only 2 - 5% of 
smokers are able to stop using tobacco without the aid of additional therapies (Okuyemi et al., 
2000). Perhaps even more startling is that following operations to repair damage done by 
chronic use of cigarettes such as lung surgery and laryngectomy, roughly 40% of people 
resume smoking (Stolerman & Jarvis, 1995). 
Tobacco smoke contains thousands of chemicals, many of which are known to have 
actions in the central nervous system (CNS; Shiffman et al., 1998). Nicotine is widely 
recognised as the chemical in tobacco products responsible for their addictive properties (US 
DHHS, 1988; Stolerman & Jarvis, 1995). For example, currently addicted smokers will 
reliably self-administer nicotine intravenously when cigarettes are not available (Harvey et al., 
2004) and rate intravenous nicotine delivery as a positive experience. Intravenously 
administered nicotine also reproduces many of tobacco's peripheral and euphoric effects 
(Henningfield et al., 1985). Direct administration of nicotine will alleviate the withdrawal 
symptoms that result from prolonged tobacco abstinence which include increased anger, 
anxiety, impatience, restlessness, difficulty concentrating and increased hunger (Hughes et al., 
1991). When the actions of nicotine on the CNS are blocked pharmacologically, smokers will 
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increase their intake in an effort to compensate for reduced nicotine efficacy (Stolerman et al., 
1973). Finally, the use of nicotine replacement therapy (NRT) during withdrawal has been 
shown to double the rate of successful abstinence from tobacco use for up to 12 months 
(Hughes et al., 1991). 
Due to the limitations inherent in human research, various animal models of nicotine 
dependence have been utilised to study the addiction related pharmacological actions of 
nicotine. Self-administration protocols, which involve the intravenous infusion of a bolus of 
drug contingent upon an operant response, have been used to characterise addictive properties 
of most drugs abused by humans (Di Chiara & Imperato, 1988). Similarly, reliable 
intravenous self-administration of nicotine has been established for multiple animal species 
including non-human primates (Goldberg et al., 1981), dogs (Risner & Goldberg, 1983), mice 
(Martellotta et al., 1995; Picciotto et al., 1998) and rats (Corrigall & Coen, 1989; Donny et al., 
1995). In rodents, the rate of responding maintained by nicotine is higher in rats than in mice 
(Le Foll & Goldberg, 2006, pg 371). Rats have been shown to be sensitive to the 
discriminative properties of nicotine (Stolerman et al., 1984) and its ability to act as an 
unconditioned stimulus in conditioned place preference tests (Le Foll & Goldberg, 2005). 
Additionally, nicotine administration produces an effect on brain reward circuitry, as indicated 
by reduced intracranial self-stimulation (ICSS) thresholds following administration (Pradhan 
& Bowling, 1971). 
Different schedules of reinforcement are used in self-administration protocols in an 
attempt to characterise different aspects of a substance’s reinforcing effects. Progressive ratio 
(PR) schedules involve implementation of a response requirement which gradually increases 
after each infusion that is earned. The final ratio completed before responding ceases is termed 
the breakpoint (BP) and has been suggested to provide a better quantitative measure of a 
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drug’s reinforcing efficacy than responding emitted under fixed-ratio (FR) schedules of 
reinforcement (Richardson & Roberts, 1996; Stafford et al., 1998). To date, reliable 
self-administration of various substances abused by humans has been demonstrated under a 
PR schedule of reinforcement (Le Foll & Goldberg, 2006) including nicotine (Donny et al., 
1999). 
Nicotine acts on the CNS via nicotinic acetylcholine receptors (nAChR; Brennan et al., 
2010). nAChRs are pentameric ligand-gated ion channels composed of a variety of subunits 
(α2 - α10, β2 - β4) in varying configurations (Wonnacott et al., 2005). Nicotine’s affinity for 
any given nAChR is related directly to the receptors subunit composition (Pidoplichko et al., 
1997). Several nicotine-produced behaviours are attenuated by nAChR antagonists and thus 
are reliant upon nAChR activation: nicotine induced locomotor activation (Benwell et al., 
1995), lowered ICSS thresholds (Pradhan & Bowling, 1971; Harrison et al., 2002) and drug 
discrimination (Stolerman et al., 1984). Additionally, the nAChR partial agonists sazetidine-A 
and varenicline effectively substitute for nicotine in the drug discrimination paradigm, and are 
self-administered by animals (Patterson et al., 2010). Pre-treatment with the nAChR 
antagonist mecamylamine during self-administration sessions attenuates responding in a 
similar fashion to saline substitution of the nicotine reinforcer (Corrigall & Coen, 1991; 
Martellotta et al., 1995; Shoaib et al., 1997; Donny et al., 1999). Further, mecamylamine is 
also known to precipitate the aversive withdrawal symptoms experienced by nicotine 
dependent animals (Watkins et al., 2000). Thus it seems that nicotine’s effects on addiction 
related brain mechanisms occur via its actions on nAChRs. 
The mesolimbic dopamine (DA) system plays a vital role in the reinforcing and 
addictive properties of addictive drugs such as cocaine, heroin and amphetamine (Wise & 
Bozarth, 1987). Further, nAChRs have been localised to mesolimbic DA containing neurons 
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in the ventral tegmental area (VTA; Calabresi et al., 1989) and their terminal fields in the 
nucleus accumbens (NAc; Pontieri et al., 1996). Acute activation of nAChRs located on VTA 
cell bodies causes excitatory release of DA into the NAc (Corrigall, 1999) that was similar to 
the DA efflux caused by other drugs of abuse (Di Chiara & Imperato, 1988). By comparison, 
chronic activation of nAChRs leads to a desensitisation of nicotine’s ability to stimulate DA 
efflux (Pidoplichko et al., 1997), a process believed to result from a functional upregulation of 
nAChRs (Parker et al., 2004). Changes in the ability of nicotine to elicit DA efflux in the NAc 
as a result of chronic exposure has been suggested to underlie the development of nicotine 
dependence (Di Chiara, 2000; Rahman et al., 2004). In particular changes in the expression of 
the α4 (Tapper et al., 2004), β2 (Picciotto et al., 1998), α6 (Parker et al., 2004) and α7 
(Schilstrom et al., 1998) nAChR subunits have been suggested as central to nicotine's long 
lasting effects on mesolimbic DA reward circuitry. 
Similar to other drugs of abuse, the ability of nicotine to act as a reinforcer is directly 
related to its ability to stimulate DA release into the NAc (Di Chiara, 2000). Supporting this 
idea, nicotine reinforced self-administration was suppressed by pretreatment with the 
non-selective DA receptor antagonist haloperidol, as well as by selective D1- and D2-like 
receptor antagonists (Corrigall & Coen, 1991). Selective antagonism of the D1-like receptor 
has also blocked nicotine-produced decreases in ICSS thresholds (Harrison et al., 2002). 
When dopaminergic neurons in the VTA were lesioned using 6-hydroxydopamine, 
self-administration of nicotine was attenuated and response patterns became similar to those 
exhibited during extinction sessions (Corrigall et al., 1992). Finally, a variety of DA receptor 
agonists will effectively substitute for nicotine, including other drugs of abuse like cocaine 
and the amphetamines (Di Chiara, 2000).  
Despite the common effects produced by nicotine and other drugs of abuse on 
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mesolimbic DA reward systems, the ability of nicotine to stimulate DA neuron activity is less 
pronounced (Sziraki et al., 1999). Nicotine's reduced ability to stimulate DA has been 
indicated whereby when given a choice, rats show a consistent preference to self-administer 
cocaine over nicotine (Manzardo et al., 2002). Furthermore, acquisition of nicotine 
self-administration is only achieved when using stricter conditions than is common for other 
substances. For example, prior training in operant procedures with a food reinforcer and food 
restricting the animals is used to facilitate acquisition of nicotine self-administration (Corrigall, 
1992). Even once nicotine is reliably self-administered it produces less robust 
self-administration than cocaine (Spealman & Goldberg, 1982) and fails to show multiple 
phenomena common to other drugs of abuse. For example, nicotine self-administration 
demonstrates considerably less sensitivity to dose than cocaine (Lynch & Carroll, 1999). 
Instead nicotine produces flat dose response curves, which are insensitive to changes in the 
unit dose (Corrigall et al., 1989; Corrigall, 1992). 
The weaker reinforcing effects exhibited by nicotine in animal models of drug use have 
contributed to the claim that nicotine is not an addictive substance (Robinson & Pritchard, 
1992; Dar & Frenk, 2004). Another commonly utilised argument against nicotine as being 
addictive involves the overall low efficacy of NRT treatments. Although NRT doubles the 
overall rate of successful smoking abstinence, this effect is short lasting, with at least 80% of 
people that used NRT resuming smoking in 6 months (Shiffman et al., 1998). Studies have 
also shown that while NRT alleviates withdrawal symptoms experienced during tobacco 
abstinence, denicotinised cigarettes were substantially more effective (Rose et al., 2000). Also, 
arguing against nicotine as an addictive substance, the rate of pure nicotine abuse or 
dependence reported amongst both smokers and non-smokers was miniscule (Hughes et al., 
1991). Even in cases where NRT was continued to be used beyond the recommended 
9 Harman, Norharman and TPM Self-administration 
 
cessation date, all prolonged users were effectively weaned off of NRT products (West et al., 
2000). These findings suggest that nicotine alone cannot explain or accurately model the 
pharmacological aspect of tobacco dependence. 
There is growing evidence that there are non-nicotinic constituents in tobacco that 
contribute to reward. Various tobacco constituents have been tested alone, and in combination 
with nicotine to determine whether any unique interactions existed regarding reinforcement 
processes. Nornicotine, a metabolite of nicotine, which also exists in tobacco smoke, 
supported stable, although weaker, self-administration responding than that produced by 
nicotine (Bardo et al., 1999). The tobacco constituent acetaldehyde enhanced nicotine 
reinforced self-administration behaviour in young rats only, without demonstrating any 
reinforcing value alone (Belluzzi et al., 2005). Clemens et al. (2009) tested a cocktail of 
tobacco alkaloids together with nicotine (anabasine, nornicotine, anatabine, cotinine and 
myosmine) and found similar synergistic actions. When combined with nicotine, the cocktail 
of alkaloids increased the development of locomotor sensitisation. Further, motivation to 
respond for the tobacco alkaloid and nicotine cocktail was greater than that for nicotine alone 
when measured using a PR schedule of reinforcement. Finally, addition of the tobacco 
alkaloids produced an inverted U-shaped dose response curve for nicotine similar to those 
reported for other drugs of abuse. 
Tobacco smoke has produced differential addiction related neuroadaptations when 
compared to nicotine alone. Firstly, there are non-nicotine constituents in tobacco smoke that 
can also bind nAChRs to produce effects on dopaminergic neurotransmission. For example, 
the tobacco constituents nornicotine, anabeseine, anabesine and N-methylanabasine all 
stimulated DA efflux and produced desensitisation of nAChRs in the striatum in vitro 
(Dwoskin et al., 1995) while the tobacco constituent cotinine specifically activated and 
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upregulated nAChRs containing the α3 and α6 subunits (O'Leary et al., 2008). Exposure to 
aqueous tobacco smoke extract suppressed the activity of serotonin (5-HT) neurons in the 
raphe nucleus to a greater extent than a matched dose of nicotine alone (Touiki et al., 2007). 
Cell culture work revealed that aqueous tobacco extract produced a greater upregulation in 
nAChR when compared to matched doses of nicotine alone (Ambrose et al., 2007). Finally, 
rats chronically exposed to tobacco smoke showed a reduction in response latencies in ICSS 
paradigms which were not detected following nicotine treatment (Small et al., 2010). These 
studies are indicative that tobacco has psychostimulant properties that do not involve a 
nicotine component. 
Of the candidate tobacco constituents likely to play a role in the additional effects of 
tobacco smoke compared to nicotine, monoamine oxidase enzyme (MAO) inhibitors have 
gathered particular interest. There are two currently identified forms of central MAO enzymes, 
A and B, which both function to break down monoamines such as DA and 5-HT. Tobacco 
smoke contains chemicals that block the actions of MAO, termed monoamine oxidase 
inhibitors (MAO-I). Positron emission tomography has revealed that MAO availability in the 
brains of current smokers was significantly less for both MAO-A (Fowler et al., 1996a) and 
MAO-B (Fowler et al., 1996b). Reduced functionality of MAO-B has also been linked to an 
upregulation of MAO-B proteins in smokers up to 15 years after quitting (Launay et al., 2009). 
These effects cannot be attributed to the actions of nicotine as it does not inhibit MAO activity 
at physiologically relevant levels (Fowler et al., 1998). Since MAO inhibition can alter 
dopaminergic and serotonergic neurotransmission (Lewis et al., 2007), this smoke-produced 
neuroadaptation is likely to impact reward. 
This idea is supported by experiments showing that rats are more willing to respond for 
nicotine on both FR and PR schedules of reinforcement when pre-treated with MAO-I 
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(Guillem et al., 2005). Because MAO-I had no effect on food reinforced responding, and were 
less effective at enhancing nicotine self-administration in rats demonstrating low response to 
novelty (Guillem et al., 2005), it was suggested that MAO-I might potentiate 
nicotine-produced sensitisation of DA circuitry. In support of this idea, nicotine produced 
behavioural sensitisation as measured by locomotor activation was sustained for substantially 
longer following MAO-I treatment (Villegier et al., 2003). 
The β -carbolines (harman and norharman), are MAO-I that exist in a variety of 
commonly consumed products, including coffee, cooked meat and tobacco smoke (Pfau & 
Skog, 2004; Herraiz, 2004). Of these, tobacco smoke provides a particularly rich source of 
these β-carbolines and recent evidence has suggested these constituents could be largely 
responsible for tobacco's MAO-I effects (Van Amsterdam et al., 2006). Harman and 
norharman levels rise in blood plasma after smoking (Breyer-Pfaff et al., 1996; 
Rommelspacher et al., 2002; Spijkerman et al., 2002) and readily cross the blood brain barrier 
(Fekkes & Bode, 1993; Rommelspacher et al., 1994). Additionally, both harman and 
norharman accumulated in the blood platelets of smokers after cigarette consumption 
(Rommelspacher et al., 2002) and have been shown to potently suppress MAO-A and MAO-B 
activity in vivo (Herraiz & Chaparro, 2005). Specifically, harman selectively inhibited 
MAO-A, while norharman inhibited both MAO forms but with lower affinity than harman.  
Harman and norharman exert neuronal effects beyond, and in addition to, MAO 
inhibition. Both of these compounds are highly active in the CNS. They activate adrenergic 
neurons in the locus coeruleus (Ruiz-Durantez et al., 2001) and mesolimbic DA neurons in the 
NAc (Ergene & Schoener, 1993). In conjunction with increased dopaminergic neuronal firing, 
systemic administration of harman (Baum et al., 1996) and norharman (Baum et al., 1995) 
altered DA dialysate levels in the rat NAc. Harman affects 5-HT systems, where systemic 
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injection produced long-lasting inhibition of dorsal raphe serotonergic neurons (Touiki et al., 
2005) and local administration increased 5-HT efflux in the hippocampus (Adell et al., 1996). 
Because the psychoactive compounds harman and norharman are present in relatively large 
quantities in tobacco smoke, there is a need to determine whether they contribute to the 
development of tobacco dependence. 
The first aim of the present study was to determine whether an aqueous tobacco smoke 
extract (tobacco particulate matter; TPM) can be intravenously self-administered by rats, and 
whether there is evidence that it is more rewarding than nicotine alone. This was 
accomplished by comparing self-administration of nicotine to a TPM solution with a matched 
nicotine concentration. Reinforcing efficacy of intravenous infusions of nicotine or TPM were 
determined using spontaneous acquisition of self-administration on a fixed ratio (FR) schedule. 
The progressive ratio (PR) schedule was then employed to determine the motivation to receive 
each drug. The second aim was to determine whether harman and norharman would alter the 
rewarding properties of self-administered nicotine. Thus, doses of harman and norharman 
were selected that were within the realms of what a smoker might be exposed to in a day and 
similar testing procedures were used as above to compare behaviour between nicotine alone 
and nicotine combined with harman and norharman treatment groups. 
 
Method 
 
Animals 
Experimentally naive male albino Sprague-Dawley rats bred in the vivarium at Victoria 
University of Wellington were used for this experiment (n = 102). Animals underwent surgery 
once they reached weights between 300-330g and were subsequently housed individually in 
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26x20x42cm Plexiglas home cages lined with pine woodchip bedding. Home cages were kept 
at 21±1 ° Celsius with 77% humidity and maintained on a 12hr light/dark cycle (light: 7:00am 
- 7:00pm). Water was made available ad-libitum in the home cage while access to rat chow 
was limited to 20g of pellets (Diet 86; Sharpes, New Zealand) per day available following the 
completion of the self-administration session. This feeding schedule has been used 
successfully by previous researchers to encourage acquisition of nicotine self-administration 
without depriving animals of dietary requirements (Corrigall, 1992; Lynch & Carroll, 1999; 
Guillem et al., 2005, 2006; Clemens et al., 2009). The experiment was run with approval from 
the Victoria University of Wellington Animal Ethics Committee and all procedures were 
consistent with the New Zealand Animal Welfare Act 1999.  
 
Apparatus 
Self-administration sessions were conducted in 28x21x21cm sized operant chambers 
(Med Associates, ENV-001) enclosed by attenuating closets maintained at 21 ° Celsius and 
controlled using a Med-PC software package (Med Associates, Med-PC IV). Each chamber 
also contained a syringe pump (Razel, Model A containing a 20.0ml syringe equipped with a 
230v 1rpm motor) responsible for intravenous delivery of drug treatment via silastic tubing. 
The tubing was protected by a spring leash (Plastics One, USA), which was anchored to the 
animal’s skullcap screw. The tubing was suspended above the animal and attached to a freely 
moving swivel (Harvard Apparatus, USA), which allowed for free movement within the 
chamber. Two levers were mounted 83mm apart on a single side of the operant chamber and 
72mm above the chamber floor, which included metal rods elevated above a layer of wood 
shavings. Depression of the right (active) lever resulted in delivery of 0.25ml of treatment 
solution accompanied by illumination of a stimulus light located directly above the active 
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lever. A 120sec time-out followed each infusion during which responses on the active lever 
did not lead to further infusions. Infusions were delivered over a 30sec interval, previously 
shown to support strong nicotine self-administration and was suggested as the best model of 
nicotine pharmacokinetics (Sorge & Clarke, 2009). Depression of the left (inactive) lever had 
no programmed consequence. Responses on both levers were recorded. 
 
Surgery 
All animals were implanted with chronically indwelling intrajugular catheters. Briefly, 
animals were placed under deep anaesthesia using Ketamine (90mg/kg; Phoenix Pharm 
Distributors LTD, New Zealand) and Xylazine (9mg/kg; Phoenix Pharm Distributors LTD, 
New Zealand) injected intraperitonealy (IP) at 1.36ml/kg. A small opening in the right chest 
wall was made to expose the jugular vein and another opening was made on the skull. The 
vein was isolated and a silastic catheter threaded subcutaneously (SC) from the skull into a 
small incision in the jugular. The catheter was secured, projecting four centimetres into the 
jugular vein and tied off above the incision. The externalised portion of the catheter, a sawn 
off and blunted 22g needle, was mounted to the skull with dental acrylic bonded to four 
anchoring screws (Centrostyle, Italy, Ref.00395) fixed into the skull. A larger screw was set in 
place on the skullcap to provide an anchor for the operant chamber spring lead. The chest wall 
incision was closed using superglue and Teramycin powder (Pfizer Animal Health, Australia) 
was applied to both surgery sites. To aid recovery, 6ml of warm Hartmann's solution was 
administered (SC) either side of the rat. 
Animals were placed in their home cages to recover and pre- and post-surgery (24hr and 
48hr), animals were administered the anti-inflammatory Carprofen (5mg/ml, SC; Norbrook 
NZ LTD, New Zealand). During the recovery period, animals received 0.2ml of daily 
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experimenter-administered intravenous (IV) infusion of heparinised (30i.u/ml) 0.9% saline 
solution containing penicillin G potassium (100,000i.u/ml). During self-administration testing, 
this penicillin solution was administered before and after the self-administration sessions. 
Once a week, when animals did not engage in self-administration testing (Sundays), 0.15ml of 
sodium pentobarbitone (50mg/ml, IV; PROVET, New Zealand) was administered to test 
catheter patency, as has been described in previous reports (Corrigall, 1992). 
 
Drugs 
The TPM was purchased from Labstat International (Ontario, Canada) and prepared as 
previously described (Ambrose et al., 2007). The nicotine content in the TPM was quantified 
(ESR), and diluted with sterile 0.9% saline so that nicotine levels were equivalent to 
30.0μg/kg/inf. The pH was adjusted to 7.0 with NaOH when necessary. The final treatment 
solution contained 80ug/ml of nicotine and daily TPM aliquots were frozen prior to use. 
(-)-Nicotine hydrogen tartrate salt (Sigma-Aldrich, New Zealand) was dissolved into sterile 
0.9% saline. The pH of the nicotine solution was adjusted to 7.0 using NaOH, necessary for 
self-administration testing (Corrigall & Coen, 1991) and separated into aliquots containing 
1mg/ml nicotine and frozen. Norharmane hydrochloride (Sigma-Aldrich, New Zealand) was 
added to nicotine aliquots before freezing at a range of concentrations (0.0, 0.013, 0.083, 
0.208mg/ml). 
Aliquots were thawed at 4 ° Celsius prior to self-administration sessions daily and 
diluted as required to the appropriate treatment dose. Remaining solution was disposed of at 
the end of each session.  
Harmane (Sigma-Aldrich, New Zealand) was dissolved in 0.5% ethanol and then 
suspended in 1% Tween-80 and administered IP at a volume of 1ml/kg 1hr prior to 
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self-administration treatment. 
An easily dissolved form of harman was not available at the commencement of the 
experiment making it impossible to combine harman solution with the nicotine aliquots. Route 
of administration, and pretreatment time were selected based on previous micro dialysis work 
(Baum et al., 1996) which demonstrated that 60min following IP administration, harman 
produced increased extracellular DA levels in the NAc, a brain region implicated in nicotine 
self-administration and the behavioural properties of other drugs of abuse (Pontieri et al., 
1996). 
 
Experiment 1 
Daily self-administration sessions (starting 7:00am, 2hr duration, Monday - Friday) 
began with the rats being weighed and flushed with penicillin solution. Rats were then 
transported to the testing room and placed into their designated chambers equipped with a 
syringe corresponding to their treatment group; nicotine (30.0μg/kg/infusion), TPM, or 
vehicle. The steel tip of the catheter was uncovered, and rats were attached to the infusion 
apparatus in the chambers and delivered an initial 0.1ml drug treatment to clear the catheter 
contents. 
Using similar protocols for the acquisition of nicotine self-administration as previous 
reports (Corrigall, 1992), animals were first placed on a single response fixed ratio (FR1) 
schedule of reinforcement. Once 10 days of FR1 responding were completed, rats were moved 
to an FR2 schedule for 5 days, and then an FR5 schedule for a minimum of 10 days prior to 
the commencement of progressive ratio (PR) testing. The experimenter delivered an additional 
3 infusions to all animals on the first day of self-administration, and 2 infusions on the second 
to encourage initial lever responses. Animals were determined to be non-acquired if they 
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emitted less than an average of four responses over their last four sessions at FR1, and were 
excluded from the rest of the study. Unlike the procedures described by Corrigall (1992) 
animals did not learn any food reinforced operant responses prior to the commencement of 
drug self-administration training. 
PR testing was conducted over several weeks and consisted of multiple 
self-administration sessions run under a PR schedule of reinforcement. The PR schedule was 
selected from previous reports (Sorge & Clarke, 2009) and was based on the equation; 5e
 (0.2 x 
Infusion)
-5 (rounded to the nearest integer), which provided the following increasing response 
requirements: 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, and 50. PR sessions occurred every 3 days, 
and were separated by self-administration sessions run under an FR5 schedule of 
reinforcement allowing animals to return to stable baseline FR5 responding between PR test 
sessions.  
 
Experiment 2 
Animals were assigned to one of the following treatment groups: nicotine 
30.0μg/kg/infusion + norharman: harman (0.0, 0.4, 2.5μg/kg/infusion: 0.0, 1.6, 
10.0μg/kg/infusion) or nicotine 75.0μg/kg/infusion + norharman: harman (0.0, 
6.25μg/kg/infusion: 0.0, 10.0μg/kg/infusion). The ratio of norharman to harman used for each 
treatment group was selected to best reflect the relative concentrations of each substance 
found in mainstream cigarette brands where the proportion of norharman was roughly 2.5 
times greater than the concentration of harman (2.19ug/cigarette, 8.52ug/cigarette respectively; 
Herraiz & Chaparro, 2005). The harman dose was scaled up to account for an expectation that 
rats which have acquired nicotine self-administration will take on average 10 infusions per 
session, as is commonly reported (Donny et al., 1995). Animals were pre-treated with 
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harman/vehicle in their home cages 1 hr before all self-administration sessions. 
The acquisition phase for experiment 2 was similar to that of experiment 1, but with 
some changes to the response criteria for progression to the next reinforcement training 
schedule. There is evidence that harman and norharman’s effects may be related to a gradual 
accumulation of these substances in tissue (Rommelspacher, 2002). To account for this, 
animals were allowed up to an additional 10 days at FR1 (20 days in total) to demonstrate 
stable responding. In addition to maintaining stable response rates prior to progression to a 
higher FR, animals were also required to demonstrate 3 consecutive days with an average 
minimum of 4 responses per session FR1, 8 responses at FR2 and 20 responses at FR5 before 
they could progress to PR testing. Animals remained on their training schedule until these 
criteria were met, or responding declined substantially. PR testing sessions were conducted in 
the same manner as in experiment 1. 
 
Data Analysis 
For both experiment 1 and 2 only the last 10 days of FR1, 3 days of FR2 and 10 days of 
FR5 for each rat before progressing on to the next phase of the experiment were analysed. 
Animals that did not complete the FR5 portion of the acquisition phase (n = 27) due to either a 
loss of catheter patency, or insufficient active lever responding, and were excluded from 
analysis. Of those that completed the FR5 phase of acquisition, animals (n = 24) that did not 
complete a minimum of three PR sessions were excluded from the PR analyses. 
All treatment groups that were part of experiment 1 were analysed together. The animals 
in experiment 2 were split into three different treatment group comparisons to assess the 
effects of: 
1) Nicotine dose (0.0, 30.0, 75.0μg/kg/infusion) 
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2) Norharman and harman (0.0 / 0.0, 0.4 / 1.6, 2.5μg/kg/infusion norharman / 10.0μg/kg 
harman) combined with the low nicotine dose (0.0, 30.0μg/kg/infusion) 
3) Norharman and harman (0.0 / 0.0, 6.25μg/kg/infusion norharman / 10.0μg/kg harman) 
combined with the high nicotine dose (0.0, 75.0μg/kg/infusion).  
 Three-way repeated measures ANOVA were conducted separately for each FR 
schedule of reinforcement (FR1, FR2, FR5) with active vs. inactive lever and session number 
as the within subject factors, and self-administration treatment as the between subject factor.  
Two-way repeated measures ANOVA with session number as the within subject factor, and 
treatment as the between subject factor, were used to analyses the last three PR breakpoints 
produced by each rat for each treatment. In the event a significant main effect of treatment 
was found in any of the analyses Fisher's least squared differences post-hoc tests were 
conducted to determine treatment specific differences. An alpha level of α = 0.05 was used for 
all significance testing. 
 
Results 
 
Experiment 1: Reinforcing efficacy and motivation to respond for tobacco particulate matter 
compared to nicotine alone 
 
Acquisition of fixed ratio responding 
Acquisition of FR responding for 30.0μg/kg/infusion nicotine (n = 8), TPM (containing 
30.0μg/kg/infusion nicotine; n = 11) and 0.9% saline (n = 10) is presented in Fig 1.1. During 
FR1 training, average daily responding increased with a main effect of day (F(5, 118) = 6.513, 
p < 0.001). A non-significant main effect of lever (F(1, 26) = 1.078, NS) suggested increases 
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Figure 1.1. Intravenous self-administration of nicotine (nic: 30.0μg/kg/infusion), TPM, or 0.9% saline for the last 
10 sessions of FR1, 3 of FR2 and 10 of FR5 completed. Data points represent group mean (+ S.E.M) number of 
responses during 2hr sessions on the active/inactive lever. Asterisks (*) indicate a significant difference between 
TPM and nic treatments (p < 0.01). Hash symbols (#) indicate a significant difference between TPM and 0.9% 
saline treatments (p < 0.001). 
 
were distributed across both the active and inactive lever. Treatment had no significant effect 
at FR1 (F(2, 26) = 1.580, NS) and there were no significant treatment X lever (F(2, 26) = 
3.282, NS) or treatment X day (9, 118) = 1.847, NS) interactions. 
Animals selectively increased active lever responding when the schedule was increased 
to FR2, as indicated by a main effect of lever (F(1, 26) = 22.415, p < 0.001). A non-significant  
main effect of day (F(2, 52) = 1.123, NS) and day X treatment interaction (F(4, 52) = 0.917, 
NS) indicated stable responding for all treatment groups. There was no evidence for any 
differences in active lever responding between treatment groups, as there was no effect of  
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Figure 1.2. Intravenous self-administration of nicotine (nic: 30.0μg/kg/infusion), TPM, or 0.9% saline for the last 
3 sessions of PR completed. Data points (A) represent group mean (+ S.E.M) breakpoints reached per session. 
Bars (B) represent group mean (+ S.E.M) breakpoints reached across all sessions. Asterisks (*) indicate 
treatments that produces significantly greater breakpoints than 0.9% saline (p < 0.01). 
 
treatment (F(2, 26) = 1.944, NS) or lever X treatment interaction (F(2, 26) = 1.804, NS). 
Preference for the active lever continued at FR5, indicated by a main effect of lever (F(1, 
26) = 90.886, p < 0.001) which was stable for all treatments during FR5 training due to a 
non-significant effect of day (F(3, 66) = 1.660, NS) and day X treatment interaction (F(5, 66) 
= 0.952, NS). A significant effect of treatment (F(2, 26) = 11.133, p < 0.001), lever X 
treatment interaction (F(2, 26) = 9.595, p < 0.01) was identified at FR5. Post-hoc tests 
revealed that the TPM solution supported significantly greater FR5 responding than 
30.0μg/kg/infusion nicotine (p < 0.01) and 0.9% saline (p < 0.001). 
 
Progressive ratio testing  
PR breakpoints (BP) for TPM (n = 11), 30.0μg/kg/infusion nicotine (n = 8) and 0.9% 
saline (n = 10) are presented in Fig 1.2. No main effect of day (F(2, 52) = 0.764, NS) or day X 
22 Harman, Norharman and TPM Self-administration 
 
treatment interaction (F(4, 52) = 0.203, NS), indicated that BP remained stable for the 
duration of test sessions for all treatments. A main effect of treatment (F(2, 26) = 7.552, p < 
0.01) indicated that there were differences in the BP produced by the different 
self-administration treatments. The post-hoc analysis revealed that the BP achieved by rats 
receiving TPM was significantly greater than those receiving 0.9% saline (p < 0.01). However, 
30.0μg/kg/infusion nicotine did not significantly differ from either treatment. 
 
Experiment 2: Effects of norharman and harman on the reinforcing efficacy and motivation to 
respond for nicotine 
 
Fixed ratio responding for different doses of nicotine 
Acquisition of nicotine (0.0, 30.0, 75.0μg/kg/infusion; n = 10, n = 14, n = 6) 
self-administration on FR1, FR2 and FR5 schedules of reinforcement are presented in Fig 2.1. 
During the FR1 phase, a main effect of day (F(4, 103) = 7.957, p < 0.001) and lever (F(1, 27) 
= 14.980, p < 0.01) suggested average daily responding increased during FR1 training with a 
preference for the active lever. Acquisition was similar for all treatments, as there was a 
non-significant day X treatment interaction (F(8, 103) = 1.819, NS). However, a main effect 
of treatment (F(2, 27) = 4.496, p < 0.05), and lever X treatment interaction (F(2, 27) = 6.397, 
p < 0.01) suggested treatment group differences in active lever responding. Post-hoc tests 
showed that responding was greater for the 75.0μg/kg/infusion nicotine condition, than for the 
0.9% saline condition (p < 0.01). 
There was no main effect of day (F(2, 54) = 0.988, NS) or day X treatment interaction 
(F(4, 54) = 0.877, NS), indicating stable responding at FR2. A main effect of lever (F(1, 27) = 
60.907, p < 0.001), treatment (F(2, 27) = 5.463, p < 0.05) and lever X treatment interaction  
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Figure 2.1. Intravenous self-administration of nicotine (nic: 0.0, 30.0, 75.0μg/kg/infusion) for the last 10 sessions 
of FR1, 3 of FR2 and 10 of FR5 completed. Data points represent group mean (+ S.E.M) number of responses 
during 2hr sessions on the active/inactive lever. Asterisks (*) indicate a significant difference between 0.0 and 
75.0μg/kg/infusion nic (*p < 0.01, **p < 0.001). Hash symbols (#) indicate a significant difference between 0.0 
and 30.0μg/kg/infusion nic (#p < 0.05, ##p < 0.001). Plus signs (+) indicate a significant difference between 30.0 
and 75.0μg/kg/infusion nic (p < 0.05). 
 
(F(2, 27) = 10.187, p < 0.01) suggested greater active lever responding, which was more 
pronounced for some treatments. Post-hoc tests revealed that FR2 responding for both 30.0 
and 75.0μg/kg/infusion nicotine was significantly greater than 0.9% saline (p < 0.05; p < 
0.01). 
Main effects of lever (F(1, 27) = 48.280, p < 0.001), treatment (F(2, 27) = 16.874, p < 
0.001) and a lever X treatment interaction (F(2, 27) = 6.713, p < 0.01) at FR5 indicated that 
the differences in active lever responding persisted. Post-hoc tests identified that 
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Figure 2.2. Intravenous self-administration of nicotine (nic: 0.0, 30.0μg/kg/infusion) + norharman (NH: 0.0, 0.4, 
2.5μg/kg/infusion) for rats pretreated with harman (H: 0.0, 1.6, 10.0μg/kg) for the last 10 sessions of FR1, 3 of 
FR2 and 10 of FR5 completed. Data points represent group mean (+ S.E.M) number of responses during 2hr 
sessions on the active/inactive lever. Asterisks (*) indicate a significant difference between 0.0 + 0.0 / 0.0 and 
30.0μg/kg/infusion nic + 0.4μg/kg/infusion NH / 1.6μg/kg H treatments (*p < 0.05, **p < 0.01, ***p < 0.001). 
Hash symbols (#) indicate a significant difference between 0.0 + 0.0 / 0.0 and 30.0μg/kg/infusion nic + 
0.0μg/kg/infusion NH / 0.0μg/kg H treatments (#p < 0.05, ##p < 0.01). Plus signs (+) indicate a significant 
difference between 30.0 + 0.4 / 1.6 and 30.0μg/kg/infusion nic + 2.5μg/kg/infusion NH / 10.0μg/kg H treatments 
(p < 0.05). Ampersands (&) indicate a significant difference between 0.0 + 0.0 / 0.0 and 30.0μg/kg/infusion nic + 
2.5μg/kg/infusion NH / 10.0μg/kg H treatments (p < 0.05). 
 
75.0μg/kg/infusion nicotine supported greater responding than 30.0μg/kg/infusion nicotine (p 
< 0.001) and 0.9% saline (p < 0.001), where 30.0μg/kg/infusion nicotine responding was also 
significantly greater than 0.9% saline (p < 0.05). At FR5, all treatments also demonstrated a 
gradual increase in responding as shown by a main effect of day (F(5, 124) = 2.449, p < 0.05), 
but no day X treatment interaction (F(9, 124) = 1.055, NS). 
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Fixed ratio responding for low dose nicotine combined with norharman and harman  
Acquisition of 0.9% saline (n = 10) or 30.0μg/kg/infusion nicotine + norharman (0.0, 
0.4, 2.5μg/kg/infusion; n = 14, n = 9, n = 7) self-administration under FR schedules of 
reinforcement following pretreatment with harman (0.0, 1.6, 10.0μg/kg) are presented in Fig 
2.2. Main effects of lever (F(1, 36) = 27.986, p < 0.001) and day (F(4, 152) = 8.485, p < 0.001) 
indicate preferential responding on the active lever which increased during FR1 training. A 
non-significant day X treatment interaction (F(13, 152) = 1,179, NS) indicated that all 
treatment groups increased responding, however a main effect of treatment (F(3, 36) = 3.858, 
p < 0.05) and lever X treatment interaction (F(3, 36) = 5.172, p < 0.01) suggested differences 
in overall active lever responses. Post hoc tests revealed that at FR1, rats treated with 
30.0μg/kg/infusion nicotine + 0.4μg/kg/infusion norharman / 1.6μg/kg harman exhibited a 
higher number of responses than those treated with 30.0μg/kg/infusion nicotine +  
2.5μg/kg/infusion norharman / 10.0μg/kg harman (p < 0.05) or 0.9% saline (p < 0.01). 
Responding continued to increase for all treatments when moved to FR2 as shown by a 
main effect of day (F(2, 72) = 3.159, p < 0.05) and non-significant day X treatment interaction 
(F(6, 72) = 1.872, NS). Similarly, a main effect of lever (F(1, 36) = 145.728, p < 0.001), 
treatment (F(3, 36) = 5.866, p < 0.01) and lever X treatment interaction (F(3, 36) = 11.296, p 
< 0.001) persisted at FR2. Post-hoc tests identified the effect of treatment to be the result of 
greater responding produced by 30.0μg/kg/infusion nicotine + 0.0μg/kg/infusion norharman / 
0.0μg/kg harman and 30.0μg/kg/infusion nicotine + 0.4μg/kg/infusion norharman / 1.6μg/kg 
harman relative to 0.9% saline (p < 0.05; p < 0.001). 
At FR5, there was no effect of day (F(5, 167) = 1.360, NS) or day X treatment 
interaction (F(14, 167) = 1.650, NS), indicating stable levels of responding for all treatment 
groups. Main effects of lever (F(1, 36) = 67.200, p < 0.001) and treatment (F(3, 36) = 3.308, p 
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< 0.05) indicated preferential responding for the active lever and treatment differences, 
however a non-significant lever X treatment interaction (F(14, 167) = 1.650, NS) suggested 
these differences were not active lever exclusive. Post-hoc analysis revealed that 
30.0μg/kg/infusion nicotine combined with 0.0, 0.4, 2.5μg/kg/infusion norharman / 0.0, 1.6, 
10.0μg/kg harman all produced significantly greater responding than 0.9% saline (p < 0.01; p 
< 0.05; p < 0.05) but were not significantly different from each other. 
 
Fixed ratio responding for high dose nicotine combined with norharman and harman  
Fig 2.3 presents acquisition of FR responding for 0.9% saline (n = 10) or 
75.0μg/kg/infusion nicotine + norharman (0.0, 6.25μg/kg/infusion; n = 6, n = 10) following 
daily pretreatment with harman (0.0, 10.0μg/kg). Responding increased during FR1 training in 
a treatment dependent manner with a main effect of day (F(4, 98) = 9.369, p < 0.001), 
treatment (F(2, 23) = 4.860, p < 0.05) and day X treatment interaction (F(9, 98) = 2.315, p < 
0.05). Post-hoc analysis indicated that 75.0μg/kg/infusion nicotine + 0.0μg/kg/infusion 
norharman / 0.0μg/kg harman treatment led to significantly greater responding than 0.9% 
saline (p < 0.01). A main effect of lever (F(1, 23) = 8.793, p < 0.01) and lever X treatment 
interaction (F(2, 23) = 5.567, p < 0.05) suggested that responding was directed towards the 
active lever, but there were treatment-produced differences in the level of active lever 
selectivity. 
Responding was stable for all treatments at FR2 with no effect of day (F(2, 46) = 1.850, 
NS) or day X treatment interaction (F(4, 46) = 1.351, NS). Main effects of lever (F(1, 23) = 
52.340, p < 0.001), treatment (F(2, 23) = 6.772, p < 0.01), and a lever X treatment interaction 
(F(2, 23) = 9.335, p < 0.01) indicated a clear preference for the active lever. Post-hoc tests 
revealed greater responding for 75.0μg/kg/infusion nicotine + 0.0 / 0.0, 6.25μg/kg/infusion 
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Figure 2.3. Intravenous self-administration of nicotine (nic: 0.0, 75.0μg/kg/infusion) + norharman (NH: 0.0, 
6.25μg/kg/infusion) for rats pretreated with harman (H: 0.0, 10.0μg/kg) for the last 10 sessions of FR1, 3 of FR2 
and 10 of FR5 completed. Data points represent group mean (+ S.E.M) number of responses during 2hr sessions 
on the active/inactive lever. Asterisks (*) indicate a significant difference between 0.0 + 0.0 / 0.0 and 
75.0μg/kg/infusion nic + 0.0μg/kg/infusion NH / 0.0μg/kg H treatments (*p < 0.01, **p < 0.001). Hash symbols 
(#) indicate a significant difference between 0.0 + 0.0 / 0.0 and 75.0μg/kg/infusion nic + 6.25μg/kg/infusion NH / 
10.0μg/kg H treatments (p < 0.01). 
 
norharman / 10.0μg/kg harman than for 0.9% saline (p < 0.01; p < 0.01). 
A main effect of day (F(5, 104) = 3.376, p < 0.01) and a non-significant day X treatment 
interaction (F(9, 104) = 1.254, NS) at FR5 indicated responding gradually increased when the 
response requirement was increased in a treatment independent manner. Preference for the 
active lever continued at FR5, with a main effect of lever (F(1, 23) = 86.590, p < 0.001). A 
main effect of treatment (F(2, 23) = 11.277, p < 0.001) and lever X treatment interaction (F(2, 
23) = 10.625, p < 0.01) indicated that there were differences in active lever responding 
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Figure 2.4. Intravenous self-administration of nicotine (nic: 0.0, 30.0, 75.0μg/kg/infusion) for the last 3 sessions 
of PR completed. Data points (A) represent group mean (+ S.E.M) breakpoints reached per session. Bars (B) 
represent group mean (+ S.E.M) breakpoints reached across all sessions. Asterisks (*) indicate treatments that 
produces significantly greater breakpoints than 0.9% saline (*p < 0.05, **p < 0.001). Hash symbols (#) indicate 
treatments that produce significantly greater breakpoints than 30.0μg/kg/infusion nic (p < 0.05). 
 
between treatment groups. This was confirmed by post-hoc analysis showing that 
75.0μg/kg/infusion nicotine + 0.0, 6.25μg/kg/infusion norharman / 0.0, 10.0μg/kg harman 
produced greater responding than 0.9% saline (p < 0.001; p < 0.01) similar to FR2. 
 
Progressive ratio testing for nicotine combined with norharman and harman  
Presented in Fig 2.4, a main effect of treatment was found when comparing 30.0 (n = 4), 
75.0μg/kg/infusion nicotine (n = 5) and 0.9% saline (n = 10; F(2, 16) = 17.517, p < 0.001). 
The 75.0μg/kg/infusion nicotine treatment consistently produced significantly greater BP than 
the 30.0μg/kg/infusion nicotine (p < 0.05) and 0.9% saline (p < 0.01) conditions. The 
30.0μg/kg/infusion nicotine condition also produced greater average BP than 0.9% saline (p < 
0.05). BP remained stable throughout testing for all treatments, evidenced by no main effect 
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Figure 2.5. Intravenous self-administration of nicotine (nic: 0.0, 30.0μg/kg/infusion) + norharman (NH: 0.0, 0.4, 
2.5μg/kg/infusion) for rats pretreated with harman (H: 0.0, 1.6, 10.0μg/kg) for the last 3 sessions of PR 
completed. Data points (A) represent group mean (+ S.E.M) breakpoints reached per session. Bars (B) represent 
group mean (+ S.E.M) breakpoints reached across all sessions. Asterisks (*) indicate treatments that produces 
significantly greater breakpoints than 0.9% saline (*p < 0.01, **p < 0.001). Hash symbols (#) indicate treatments 
that produce significantly greater breakpoints than 30.0μg/kg/infusion nic + 2.5μg/kg/infusion NH / 10.0μg/kg H 
(p < 0.05). 
 
of day (F(2, 32) = 2.375, NS) or day X treatment interaction (F(4, 32) = 0.858, NS). 
Comparing 30.0μg/kg/infusion nicotine combined with 0.0/ 0.0 (n = 4), 0.4 / 1.6 (n = 3) 
and 2.5μg/kg/infusion norharman / 10.0μg/kg harman (n = 4) and 0.9% saline (n = 10; Fig 2.5) 
revealed a main effect of treatment (F(3, 17) = 19.291, p < 0.001). Post-hoc tests showed that 
30.0μg/kg/infusion nicotine plus 0.0/ 0.0 and 0.4μg/kg/infusion norharman / 1.6μg/kg harman 
produced significantly greater BP than both the 0.9% saline (p < 0.001; p < 0.001) and 
30.0μg/kg/infusion nicotine plus 2.5μg/kg/infusion norharman / 10.0μg/kg harman (p < 0.05; 
p < 0.05) conditions. Additionally, 30.0μg/kg/infusion nicotine plus 2.5μg/kg/infusion 
norharman / 10.0μg/kg harman also yielded greater BP than 0.9% saline (p < 0.01). A main 
effect of day (F(2, 29) = 8.987, p < 0.01) and non-significant day X treatment interaction (F(5, 
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Figure 2.6. Intravenous self-administration of nicotine (nic: 0.0, 75.0μg/kg/infusion) + norharman (NH: 0.0, 
6.25μg/kg/infusion) for rats pretreated with harman (H: 0.0, 10.0μg/kg) for the last 3 sessions of PR completed. 
Data points (A) represent group mean (+ S.E.M) breakpoints reached per session. Bars (B) represent group mean 
(+ S.E.M) breakpoints reached across all sessions. Asterisks (*) indicate treatments that produce significantly 
greater breakpoints than 0.9% saline (*p < 0.01, **p < 0.001). 
 
29) = 2.330, NS) indicated that BP systematically decreased for all treatments following 
repeated testing. 
In Fig 2.6, 75.0μg/kg/infusion nicotine is shown combined with 0.0 / 0.0 (n = 5) or 
2.5μg/kg/infusion norharman / 10.0μg/kg harman (n = 6) and 0.9% saline (n = 10) treated rats. 
There was a main effect of treatment (F(2, 18) = 12.576, p < 0.001) for PR-produced BP. The 
75.0μg/kg/infusion nicotine and 0.0 / 0.0 or 6.25μg/kg/infusion norharman / 10.0μg/kg 
harman treatments produced significantly greater BP than the 0.9% saline (p < 0.001; p < 0.01) 
condition. There were no main effects of day (F(2, 36) = 0.444, NS) or day X treatment 
interaction (F(4, 36) = 0.363, NS), indicating that BP remained stable for the duration of 
testing. 
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Discussion 
 
The present study is the first to demonstrate that rats will intravenously self-administer 
an aqueous tobacco smoke extract (TPM). The results revealed that TPM was more rewarding 
than a matched dose of pure nicotine as shown by increased responding on FR5 and higher 
breakpoints than nicotine and vehicle control groups. A role for the smoke constituents, 
harman and norharman, in these effects was also investigated. Low dose harman and 
norharman combined with low dose nicotine initially produced a small enhancement in FR1 
responding, but there was a tendency to reduce FR responding and decrease BP for nicotine at 
the higher harman and norharman doses.  
For experiment 1 animals were trained to intravenously self-administer nicotine, TPM 
(Ambrose et al., 2007) containing an equivalent volume of nicotine, or vehicle delivered under 
fixed ratio (FR) schedules. The results showed that nicotine and TPM were both more 
effective at maintaining self-administration under an FR schedule of reinforcement than 
vehicle, demonstrating compensatory increases in active lever responding when the FR 
requirements were increased (Figure 1.1). However, low dose nicotine (30.0μg/kg/inf) did not 
support robust self-administration (Figure 1.1). The nicotine group did not exhibit responding 
above control levels on FR1. Responding increased on FR2 relative to the controls, but when 
the response requirement was increased to FR5, responding dropped and was again no 
different to controls. These results were comparable to previous nicotine self-administration 
studies that have shown that when the response requirement is increased; motivation to 
maintain a similar nicotine intake is low (Clemens et al., 2009; Clemens et al., 2010) or there 
was failure to observe self-administration altogether (Guillem et al., 2005; 2006). This general 
pattern extended to the PR tests in the present study, where overall BP were not significantly 
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higher for nicotine compared to controls (Figure 1.2). 
Acquisition of self-administration at FR1 and FR2 did not differ between treatments, 
suggesting that TPM did not produce an acutely more rewarding experience compared to 
nicotine at the start of the experiments. However, TPM supported greater responding at FR5 
and produced a higher BP in PR tests than the nicotine and vehicle control groups (Figure 1.2), 
indicating that the rats were more motivated to receive TPM. These results suggest that 
chronic exposure to TPM might be required in combination with an increased response 
requirement for the differences between treatment groups to become evident. Interestingly, 
increasing response requirements are required to identify differences between the motivation 
to work for intravenous nicotine and placebo when testing human tobacco smokers (Harvey et 
al., 2004). 
Tobacco smoke extract exposure has produced effects on addiction related reward 
pathways in the brain which are not produced by nicotine alone. For example Small et al. 
(2010) found that tobacco smoke exposure reduced response latencies in an intra-cranial 
self-stimulation paradigm, whilst nicotine did not. The ability to reduced response latencies is 
a property of psychostimulant drugs that have been implicated in reinforcement processes 
(Wise & Bozarth, 1987). Acquisition of intravenous nicotine self-administration and the 
development of nicotine dependence rely on acute activation of nAChRs and chronic 
desensitisation and upregulation of these receptors in mesoaccumbens DA circuitry (Brennan 
et al., 2010). Since TPM has upregulated nAChRs to a greater extent than an equivalent dose 
of nicotine (Ambrose et al., 2007), it is possible that upregulated nAChRs could underlie the 
enhanced behavioural response to TPM observed in the present study. Furthermore, TPM 
alone exhibits strong MAO inhibitory activity (Lewis and Truman, ESR unpublished data) and 
tobacco smoke exposure produces brain MAO inhibition (Fowler et al., 1996a; 1996b; 
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Sharma & Brody, 2009), whereas nicotine injection does not produce these effects (Fowler et 
al., 1998). Thus, at least one of these TPM-produced neuroadaptations could account for the 
observed enhancement of reward.   
The purpose of experiment 2 was to determine whether harman and norharman could 
enhance the rewarding effects of two different concentrations of intravenous nicotine. The 
results from experiment 2 revealed that the larger nicotine dose (75.0μg/kg/infusion) 
supported greater self-administration than vehicle at all FR schedules tested, and better FR5 
responding than the smaller nicotine dose (30.0μg/kg/infusion) (Figure 2.1). Greater BP were 
also produced by the higher nicotine dose than both the lower nicotine dose and vehicle, 
which were also significantly different from each other, indicating nicotine dose dependently 
increases in reinforcing efficacy. 
These nicotine dose-effect findings compare with others, where higher doses of nicotine 
(60 and 90.0μg/kg/infusion) supported better FR responding (Chaudhri et al., 2007) and also 
yielded increased BP on PR compared to the lower doses (Donny et al., 1999; Chaudhri et al., 
2007). Interestingly, when nicotine paired visual cues were removed the lower doses would 
only weakly support self-administration if at all (Chaudhri et al., 2007, Sorge & Clarke, 2009). 
Further, only the very high dose (90.0μg/kg/infusion) maintained self-administration above 
control levels (Chaudhri et al., 2007). Chaudhri’s (2007) results suggest that only high dose 
nicotine self-administration is maintained by primary reinforcing properties.  
The high nicotine dose does not represent levels found in tobacco smoke. The most 
representative nicotine dose of a ‘puff’ on a cigarette was purported to be 3.0μg/kg/infusion, 
where the 30.0μg/kg/infusion dose used in the present study was at the maximal end of the 
smoke exposure range (Sorge & Clarke, 2009). Therefore the 75.0μg/kg/infusion dose served 
as a ‘positive control’ and demonstrated that when the nicotine dose is high enough, nicotine 
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more closely resembles other reinforcing psychostimulants in self-administration tests. 
Overall responding for the 30.0μg/kg/infusion (same as nicotine content of TPM) was weak, 
supporting the idea that nicotine cannot fully account for the reinforcing effects of TPM. 
Overall levels of self-administration observed in this study were lower than what is 
frequently reported for nicotine, particularly at the 30.0μg/kg infusion dose. Studies using 
similar protocols to this report normally find rats will consistently respond for approximately 
10 infusions of nicotine (Donny et al., 1995). However, similar levels of responding to those 
in this report have been reported elsewhere (Shoaib et al., 1997). There are multiple 
methodological features which might account for the less than typical response observed in 
the present study. Animals in this study were not initially trained to respond for a food 
reinforcer as has been previously recommended (Corrigall, 1992). The only visual stimulus 
presented during presentation of a nicotine infusion consisted of a key light; however previous 
reports have turned off the house lighting during the timeout period, which facilitated the 
acquisition of nicotine self-administration (Caggiula, 2002). Further, the present 
self-administration sessions were conducted during the light cycle, whereas it has been 
reported that rodents trained during the dark cycle tended to perform better (Paterson et al., 
2010). Despite these methodological differences and the low overall rate of active lever 
responding, nicotine still maintained significantly more responding than vehicle. 
The last major methodological difference which may account for lower rates of nicotine 
self-administration in this study is the longer 30sec infusion time used. Traditionally nicotine 
infusions are delivered over 1sec, an infusion time thought to best represent the rapid bolus of 
nicotine delivered to the brain following the puff of a cigarette (Rose et al., 1999). This view 
has been supported by previous work which found that a 1sec infusion of nicotine better 
supports more robust self-administration responding, than nicotine delivered over longer 
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durations (Valentine et al., 1997). However, an infusion time of 30sec has recently been 
argued to better reflect nicotine pharmacokinetics during cigarette smoking (Sorge & Clarke, 
2009). Sorge and Clarke (2009) looked at the differences produced by the change in infusion 
time and found 30s infusions with a 120s timeout supported greater active lever responding 
than 3s infusion on both FR and PR schedules of reinforcement. They also found rats 
demonstrated a preference for 30sec infusions of nicotine compared to 3sec infusions. 
Increased responding under a 30sec infusion time found by Sorge & Clarke (2009) make it 
unlikely the infusion time chosen for this study contributed towards the lower levels of 
responding.  
Experiment 2 revealed that the treatment group that received high dose harman and 
norharman and high dose nicotine (75.0μg/kg/infusion) did not exhibit much change in 
behaviour when compared to the nicotine only group (75.0μg/kg/infusion) (Figure 2.3). 
Initially on FR1, the harman and norharman group exhibited lower levels of responding than 
the nicotine only group, although these differences disappeared when the response 
requirement was increased. There were no differences in BP on PR tests (Figures 2.6).  
When harman and norharman were combined with low dose nicotine 
(30.0μg/kg/infusion) a similar suppression of responding at lower FR schedules was observed 
for the highest dose of harman and norharman (Figure 2.2). This difference vanished once the 
response schedule was increased to FR5, with all treatments supporting greater 
self-administration than vehicle. All treatments also produced greater BP than vehicle, 
however, the highest dose of harman and norharman combined with nicotine supported lower 
BP than the other groups (other groups (Figure 2.5). These results suggest that harman and 
norharman might reduce the reinforcing efficacy of nicotine. 
The inability of harman and norharman to increase the reinforcing efficacy of 
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intravenous nicotine suggests they are not responsible for the greater BP produced by TPM 
treatment in experiment 1. In fact, the results of experiment 2 suggest that norharman and 
harman may reduce the reinforcing efficacy of nicotine. These findings are unexpected as 
MAO-I treatment has previously been shown to enhance intravenous self-administration of 
nicotine (Guillem et al., 2005; 2006). These inconsistencies are likely the result of the type of 
MAO-I used (tranylcypromine and phenelzine), and doses selected for treatment. These 
MAO-I have effects additional to their ability to inhibit MAO, and potently increase 
concentrations of catecholamines such as DA and 5-HT similar to other drugs of abuse (Baker 
et al., 1992). The dose of norharman used by Guillem et al. (2006) that enhanced BP for 
nicotine self-administration was also substantially larger than what a cigarette smoker might 
be exposed to.  
The finding that harman and norharman reduce the reinforcing efficacy of the lowest 
dose of nicotine tested however was contrary to the hypothesis of this study. Both harman and 
norharman produce an increase in synaptic DA in the NAc (Baum et al., 1995; 1996), which 
would be expected to support or enhance self-administration behaviour (Pontieri et al., 1996; 
Di Chiara, 2000). However, harman and norharman have effects on catecholamines other than 
DA and these effects could inhibit behaviour. For example, harman stimulated 5-HT activity 
at low concentrations (Baum et al., 1996) and increased synaptic levels of 5-HT in the NAc 
inhibits the firing of DA neurons located in the VTA, believed to be nicotine’s primary site of 
action (Corrigall, 1999). 
Suppression of the reinforcing properties of nicotine was most pronounced at the lowest 
dose of nicotine combined with the highest dose of harman and norharman (Figure 2.5). 
Interestingly, this treatment condition received the highest dose of harman (10μg/kg). Harman 
potently inhibits MAO-A, without actions on MAO-B (Herraiz & Chapparo, 2005). Previous 
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studies have shown that inhibition of MAO-A, but not MAO-B, produced changes in nicotine 
reinforced self-administration (Guillem et al., 2006). While both forms of MAO are known to 
inhibit DA (Berlin & Anthenelli, 2001), MAO-A is preferentially responsible for the 
degradation of 5-HT (Celada & Artigas, 1993). As a result, the suppression of nicotine 
reinforcing efficacy might be due to a greater increase in synaptic 5-HT relative to DA. 
Increases in 5-HT activity have been associated with inhibition of cocaine 
self-administration. Animals trained to self-administer cocaine on an FR schedule of 
reinforcement made fewer responses when their daily diet contained L-tryptophan, a 5-HT 
synthesis precursor that increases CNS levels of 5-HT (Carroll et al., 1990). When rats were 
tested on a PR schedule of reinforcement with cocaine as a reinforcer, BP achieved following 
lesioning of 5-HT neurons using 5,7-DHT were markedly increased (Loh & Roberts, 1990). 
Further, rats pretreated with 5-HT agonists showed reduced self-administration of cocaine, an 
effect that was more pronounced at low unit doses, and high unit costs (Peltier & Schenk, 
1993). These findings suggest that 5-HT primarily plays a role in the inhibitory modulation of 
cocaine’s reinforcing efficacy. 
The TPM treatment used in this study is derived from tobacco smoke which contains 
harman and norharman (quantified by ESR; Christchurch, New Zealand). However, the 
concentration of harman and norharman found in the TPM solution does not appear to be 
sufficient to reduce the reinforcing efficacy of this treatment. There are two likely 
explanations for this lack of inhibition. First, nAChR upregulation and/or increased 
stimulation of these receptors might enhance reward, where nicotine is not the only tobacco 
constituent that acts via nAChRs. For example, nornicotine, anabeseine, anabesine and 
N-methylanabasine are all smoke constituents able to stimulate DA efflux and desensitise 
nAChRs in vitro (Dwoskin et al., 1995). Similarly, cotinine causes upregulation of nAChRs 
38 Harman, Norharman and TPM Self-administration 
 
(O'Leary et al., 2008). These effects, when combined with the actions of nicotine, might 
produce enough activation of nAChRs on DA neurons to overcome any inhibition produced 
by harman and norharman. Alternately, concurrent inhibition of 5-HT by other tobacco 
constituents (Touiki et al., 2007) could counteract the stimulatory actions of harman and 
norharman on the serotonergic system. In particular, nAChRs located on 5-HT containing 
cells projecting to various brain regions could be candidates for such a blockade (Seth et al., 
2002). 
This study determined the relative reinforcing efficacy of an aqueous tobacco extract, 
nicotine, and nicotine combined with harman and norharman in rats. TPM possessed 
significantly greater reinforcing efficacy than nicotine, an effect which may be related to 
differences in the ability of nicotine and TPM to upregulate nAChRs. However, the 
hypothesised role for harman and norharman in the differences between TPM and nicotine 
was not supported. Harman and norharman significantly reduced the reinforcing efficacy of 
intravenous nicotine at the lowest unit dose of nicotine tested. These β-carbolines are known 
to have multiple central actions including MAO inhibitory properties and the ability to 
increase synaptic DA and 5-HT. Increases in 5-HT activity causes a reduction in the 
reinforcing efficacy of psychostimulants such as cocaine, particularly at low unit doses and 
high unit costs. Thus, excitatory effects of harman and norharman on the serotonergic system 
might explain the reduction in nicotine reinforcing efficacy observed. Although the aqueous 
tobacco extract used in this study contained measurable levels of harman and norharman, the 
present results indicate that other tobacco constituents must be responsible for the enhanced 
reinforcing efficacy of TPM. 
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